{"product_id":"amicusrx-business-model-canvas","title":"Amicus Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas for a Rare-Disease Biotech: Strategic, Scalable, Investment-Ready\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind Amicus Therapeutics with our concise Business Model Canvas—three to five actionable sentences reveal how the company creates value, scales therapies, and monetizes rare-disease innovation. Ideal for investors and strategists seeking a ready-to-use roadmap; download the full Canvas in Word and Excel for a complete, section-by-section analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and clinical research alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and rare disease centers accelerate target discovery and translational research by granting Amicus access to well-characterized patient cohorts and longitudinal natural history datasets, supporting precise trial populations. Joint studies enable biomarker validation and optimized trial design, enhancing regulatory readiness. These alliances boost scientific credibility and increase peer-reviewed publication output, reinforcing Amicus’s position in rare disease research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers and suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized CMOs manufacture Amicus small-molecule and biologic therapies to GMP standards, ensuring batch release and regulatory compliance. Secure supply of critical enzyme, chaperone, and excipient inputs reduces program risk and supports clinical timelines; by 2024 dual sourcing became industry standard. Rigorous quality agreements and dual sourcing protect continuity, while scale-up partners enable global launches and commercial growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy and foundations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient advocacy groups and foundations accelerate patient identification, education and trial awareness—critical for rare diseases like Fabry, which affects about 1 in 40,000 males; globally ~300 million people live with rare diseases (WHO). Foundations inform unmet needs and patient-reported outcomes used in study design and registries. Advocacy input strengthens access strategies and policy engagement, while co-created programs improve adherence and real-world evidence generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostics and genomic testing networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiagnostics and genomic testing partners shorten time-to-diagnosis for rare diseases, and in 2024 Amicus leveraged sponsored testing and reflex panels to expand patient identification and enrollment. Data-sharing partnerships improved genotype-phenotype correlations used in trial design and labeling, while integration with specialty clinics streamlined therapy initiation and follow-up.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSponsored testing expands eligible pools (2024)\u003c\/li\u003e\n\u003cli\u003eReflex panels speed diagnosis\u003c\/li\u003e\n\u003cli\u003eData-sharing refines genotype-phenotype\u003c\/li\u003e\n\u003cli\u003eClinic integration shortens therapy start\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and market access partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialist consultants and local affiliates navigate regulatory approvals and HTA pathways for Amicus, coordinating submissions, local clinical evidence and stakeholder engagement to secure market access. They optimize labeling, risk-management plans and post‑marketing evidence packages to support safety and effectiveness claims. Localized pricing and reimbursement strategies plus ongoing compliance support sustain product lifecycle value across jurisdictions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory navigation: local approvals and HTA engagement\u003c\/li\u003e\n\u003cli\u003eEvidence optimization: labeling, RMPs, post‑market studies\u003c\/li\u003e\n\u003cli\u003eMarket access: country-specific pricing and reimbursement\u003c\/li\u003e\n\u003cli\u003eCompliance: continuous lifecycle support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP dual-sourcing + academic cohorts de-risk trials; Fabry \u003cstrong\u003e1:40,000\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcademic and rare-disease centers supply well-characterized cohorts and natural history datasets to de-risk trials. CMOs ensure GMP manufacturing with dual sourcing becoming standard by 2024 to secure supply and scale. Advocacy groups and diagnostics expand ID\/enrollment; Fabry ~1 in 40,000 males and rare diseases affect ~300 million globally.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\/centers\u003c\/td\u003e\n\u003ctd\u003eCohorts, biomarkers\u003c\/td\u003e\n\u003ctd\u003eNatural history datasets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eGMP, scale\u003c\/td\u003e\n\u003ctd\u003eDual sourcing standard (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\/Diagnostics\u003c\/td\u003e\n\u003ctd\u003ePatient ID\/enrollment\u003c\/td\u003e\n\u003ctd\u003eFabry 1:40,000; rare ~300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Amicus Therapeutics outlining nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, partners, and cost structure—reflecting its rare-disease R\u0026amp;D, licensing, and commercialization strategy. Ideal for presentations and investor discussions, it includes competitive advantages, SWOT-linked insights, and practical validation points for analysts and entrepreneurs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level one-page Business Model Canvas for Amicus Therapeutics that quickly identifies core components and pain points, saving hours of structuring while remaining shareable and editable for team collaboration and boardroom-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease R\u0026amp;D and pipeline advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery and preclinical work targets lysosomal and genetic disorders, supporting a pipeline of over 10 preclinical and clinical programs as of 2024 and leveraging Galafold (migalastat) approvals in the US, EU and Japan to inform translational strategy.\u003c\/p\u003e\n\u003cp\u003eCandidate optimization focuses on efficacy, safety and dosing convenience to improve patient adherence and commercial value, while biomarker and assay development enables genotype-driven precision medicine for targeted enrollment.\u003c\/p\u003e\n\u003cp\u003eRegular portfolio reviews prioritize assets with the highest clinical and commercial impact, reallocating resources toward programs with clear regulatory pathways and unmet-need potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trials and evidence generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal clinical programs validate safety, efficacy and functional outcomes, exemplified by Amicus approval of Galafold in 2018 for amenable Fabry patients. Enrichment strategies use genotypes and biomarkers to increase trial power. Natural history comparators and registries, such as the Fabry Registry, provide essential context. Post-approval studies expand labels and capture real-world effectiveness and safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and quality management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcess development ensures potency and batch-to-batch consistency for Amicus biologics and small molecules, using standardized assays and release criteria. GMP oversight covers suppliers, contract manufacturing organizations, and distribution partners to secure product quality and traceability. Continuous validation programs and document control maintain regulatory compliance across markets. Technology transfers to regional sites enhance supply resilience and reduce single‑source risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory submissions and pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCompilation and submission of NDA\/MAA dossiers drives regulatory approvals and lifecycle variations, with submissions and responses managed across regions as of 2024.\u003c\/p\u003e\n\u003cp\u003eContinuous pharmacovigilance aggregates safety signals across markets and indications, informing risk management plans and REMS which are executed and updated; label optimization follows new data and guidance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eRegulatory filings: centralized NDA\/MAA compilation\u003c\/li\u003e\n\u003cli\u003eSafety: cross‑market signal detection\u003c\/li\u003e\n\u003cli\u003eRisk: active REMS and RMP updates\u003c\/li\u003e\n\u003cli\u003eLabeling: iterative optimization\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access, medical education, and launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHTA dossiers and value communications secure reimbursement by demonstrating clinical and economic benefit; for example Galafold (migalastat) is approved in the US and EU as of 2024 and underpins payer talks. Medical affairs educates HCPs, supports KOL engagement and real-world evidence generation. Patient services facilitate onboarding and adherence through case management and hub services. Launch planning aligns supply, pricing, market access and field execution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHTA \u0026amp; reimbursement: dossier development, value dossiers\u003c\/li\u003e\n\u003cli\u003eMedical education: HCP training, KOL partnerships\u003c\/li\u003e\n\u003cli\u003ePatient services: onboarding, adherence support\u003c\/li\u003e\n\u003cli\u003eLaunch ops: supply, pricing, field alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing a \u003cstrong\u003e10+\u003c\/strong\u003e program pipeline for lysosomal and genetic disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery and preclinical work targets lysosomal and genetic disorders, supporting a pipeline of over 10 preclinical and clinical programs as of 2024 and leveraging Galafold approvals in the US, EU and Japan (Galafold approved 2018). Candidate optimization, biomarker-driven enrollment and GMP process development advance clinical readiness and commercial quality. Regulatory submissions (NDA\/MAA), pharmacovigilance, HTA, patient services and launch ops sustain product lifecycle.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline programs\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10\u003c\/td\u003e\n\u003ctd\u003epreclinical+clinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalafold approvals\u003c\/td\u003e\n\u003ctd\u003eUS, EU, Japan\u003c\/td\u003e\n\u003ctd\u003eapproved 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey registry\u003c\/td\u003e\n\u003ctd\u003eFabry Registry\u003c\/td\u003e\n\u003ctd\u003enatural history comparator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Amicus Therapeutics Business Model Canvas, not a mockup—it's a direct extract from the final file you'll receive after purchase. When you complete your order you'll get this exact, fully editable document in Word and Excel, structured and formatted exactly as shown. No placeholders or surprises—what you see is what you'll download and use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161440235897,"sku":"amicusrx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/amicusrx-business-model-canvas.png?v=1762693062","url":"https:\/\/portersfiveforce.com\/products\/amicusrx-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}